title: Mouse models of fukutin-related protein mutations show a wide range of disease phenotypes.
abstract: Dystroglycanopathies are characterized by a reduction in the glycosylation of alpha-dystroglycan (α-DG). A common cause for this subset of muscular dystrophies is mutations in the gene of fukutin-related protein (FKRP). FKRP mutations have been associated with a wide spectrum of clinical severity from severe Walker-Warburg syndrome and muscle-eye-brain disease with brain and eye defects to mild limb-girdle muscular dystrophy 2I with myopathy only. To examine the affects of FKRP mutations on the severity of the disease, we have generated homozygous and compound heterozygous mouse models with human mutations in the murine FKRP gene. P448Lneo+ and E310delneo+ mutations result in severe dystrophic and embryonic lethal phenotypes, respectively. P448Lneo+/E310delneo+ compound heterozygotes exhibit brain defects and severe muscular dystrophies with near absence of α-DG glycosylation. Removal of the Neo(r) cassette from the P448Lneo+ homozygous mice eliminates overt brain and eye defects, and reduces severity of dystrophic phenotypes. Furthermore, introduction of the common L276I mutation to generate transgenic L276Ineo+ homozygous and L276Ineo+/P448Lneo+ and L276Ineo+/E310delneo+ compound heterozygotes results in mice displaying milder dystrophies with reduced α-DG glycosylation and no apparent brain defects. Limited sampling and variation in functionally glycosylated α-DG levels between and within muscles may explain the difficulties in correlating FKRP expression levels with phenotype in clinics. The nature of individual mutations, expression levels and status of muscle differentiation all contribute to the phenotypic manifestation. These mutant FKRP mice are useful models for the study of disease mechanism(s) and experimental therapies.
authors.affiliation: McColl-Lockwood Laboratory for Muscular Dystrophy Research, Neuromuscular/ALS Center, Carolinas Medical Center, Charlotte, NC 28231, USA. anthony.blaeser@carolinashealthcare.org
authors.forename: Anthony
authors.initials: A
authors.lastname: Blaeser
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Keramaris
authors.forename: Yiumo M
authors.initials: YM
authors.lastname: Chan
authors.forename: Susan
authors.initials: S
authors.lastname: Sparks
authors.forename: Dale
authors.initials: D
authors.lastname: Cowley
authors.forename: Xiao
authors.initials: X
authors.lastname: Xiao
authors.forename: Qi Long
authors.initials: QL
authors.lastname: Lu
mesh_terms: D000818:Animals; D015153:Blotting, Western; D004195:Disease Models, Animal; D005260:Female; D005455:Fluorescent Antibody Technique; D006031:Glycosylation; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009136:Muscular Dystrophies / Q000145:classification* / Q000209:etiology / Q000473:pathology*; D009154:Mutation; D010430:Pentosyltransferases; D010641:Phenotype; D011506:Proteins / Q000502:physiology*; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014166:Transferases
chemical_list: D011506:Proteins; D012333:RNA, Messenger; D014166:Transferases; C499093:Fkrp protein, mouse; D010430:Pentosyltransferases